Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that spironolactone may be an effective therapy for a subgroup of hirsute patients, as it reduced plasma testosterone and improved certain hair growth measures.

This study reports the preparation of a key intermediate for finasteride and epristeride with a 69% overall yield from pregnenolone acetate.

This study evaluated Korean herbal compounds in silico and identified Biochanin A, Saponin Re, and Emodin as potential topical treatments for androgenetic alopecia, each with specific safety and efficacy considerations.

This trial will compare the effectiveness of spironolactone to doxycycline for treating acne in adult females, potentially offering an alternative to antibiotics and isotretinoin.

This study found that an extract from the root of Sophora flavescens Aiton significantly improved hair growth in patients with androgenetic alopecia over 6 months.

This study found that Spironolactone-loaded ethosomal gels provided superior skin permeation and deposition compared to niosomal gels in rabbit skin, suggesting that ethosomal gels could be a promising formulation for further clinical studies on treating androgenic alopecia.

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

This study aims to conduct the first double-blind randomized trial comparing spironolactone and doxycycline for female acne treatment, with the goal of establishing spironolactone as a potentially superior alternative, especially given concerns about antibiotic resistance.

In this study, in silico screening and molecular simulations identified β-sitosterol and brassicasterol as stable potential inhibitors of 5α-reductase1, suggesting they could be explored for androgenic alopecia treatment.

In this study, researchers formulated a topical gel containing β-sitosterol for alopecia treatment and found it demonstrated good 5 alpha reductase inhibitory activity in vitro, comparable to a commercial product, indicating its potential for further antiandrogenic activity investigation.

This study found petroleum ether to be more effective than methanol at extracting β-sitosterol from Eclipta alba, with higher concentrations detected using HPTLC and HPLC methods. The extracted materials contained metals within safety limits.

This source suggests that spironolactone, a potassium-sparing diuretic, is underutilized in dermatology despite evidence showing its potential benefits for female acne, hidradenitis suppurativa, and female androgenetic alopecia, noting its long-term safety and reduced need for additional testing in young women.

This study found that retinoic acid and a retinol complex formulation showed different permeation and compound localization in a skin equivalent model, with unique lipid changes observed with only the retinol formulation.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This in-silico study identified several compounds as potential Vitamin D Receptor agonists, with Dolichosterone showing the strongest binding energy.

This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.

This study found that phytosterols extracted from moringa seed oil may act as potential anti-alopecia agents by inhibiting the 5α-reductase enzyme, with ergostadienol showing particularly high affinity and stability in in silico simulations.

This study investigated a novel treatment for androgenetic alopecia, combining nanotechnology with a substance called β-sitosterol and laser therapy, and found that this combination showed promise in promoting hair growth without causing irritation or cytotoxicity.

This study found that oral spironolactone 100 mg daily for 24 weeks improved terminal hair counts and diameters in premenopausal women with female pattern hair loss when used alongside minoxidil, despite a higher incidence of menstrual irregularities.